NDA 212994 · Commave Sub
Azstarys
Dexmethylphenidate Hydrochloride, Serdexmethylphenidate Chloride · Oral
NovelCDER novel approval, Mar 2, 2021: To treat attention deficit hyperactivity disorder
Last checked: Nov 20, 2026Latest source record: Sep 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Mar 2, 2021
Approved uses
1
Original approval plus efficacy supplements
Registered trials
33
11 Phase 3, 3 recruiting
FAERS reports
741
114 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: ABUSE, MISUSE, AND ADDICTION AZSTARYS has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including AZSTARYS, can result in overdose and death [see Overdosage ( 10 )], and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. Before prescribing AZSTARYS, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout AZSTARYS treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction [see Warnings and Precautions ( 5.1 ) and Drug Abuse and Dependence ( 9.2 )]. WARNING: ABUSE, MISUSE, AND...
What it is approved for
From the label in effect May 11, 2026.
AZSTARYS is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years of age and older. Limitations of Use The use of AZSTARYS is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage [see Warnings and Precautions ( 5.7 ), Use in Specific Populations ( 8.4 )]. AZSTARYS is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years of age and older. ( 1 ) Limitations of Use The use of AZSTARYS is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage (5.7, 8.4).
Mechanism: Serdexmethylphenidate is a prodrug of dexmethylphenidate. Dexmethylphenidate HCl is a central nervous system (CNS) stimulant. The mode of therapeutic action in ADHD is not known.
Therapeutic areas: Psychiatry
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 2, 2021 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination NovelLetterLabelMedication Guide
3 products under this application
- AZSTARYS · DEXMETHYLPHENIDATE HYDROCHLORIDE EQ 7.8MG BASE; SERDEXMETHYLPHENIDATE CHLORIDE EQ 39.2MG BASE · CAPSULE, ORAL · Prescription
- AZSTARYS · DEXMETHYLPHENIDATE HYDROCHLORIDE EQ 10.4MG BASE; SERDEXMETHYLPHENIDATE CHLORIDE EQ 52.3MG BASE · CAPSULE, ORAL · Prescription
- AZSTARYS · DEXMETHYLPHENIDATE HYDROCHLORIDE EQ 5.2MG BASE; SERDEXMETHYLPHENIDATE CHLORIDE EQ 26.1MG BASE · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Dexmethylphenidate" as an intervention, any sponsor and status, largest first.
- Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity DisorderPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT01074294 · 740 participants · Start Mar 16, 2010 · Primary completion Jun 20, 2011
Drug: OPDC-34712; Placebo and 1 more · For: Attention Deficit Hyperactivity Disorder
Sites: Little Rock, Arkansas; Beverly Hills, California; Irvine, California · 35 sites in all
- AWARE: Management of ADHD in Autism Spectrum DisorderPivotal-lookingRecruiting
Daniel CouryAcademic, hospital or other
NCT05916339 · 500 participants (planned) · Start Oct 1, 2023 · Primary completion Jan 1, 2027
Drug: Randomization to either Amphetamine (AMP) class of stimulant medication or Methylphenidate (MPH) class of stimulant medication; Randomization to either Alpha 2 agonist class of medication or alternate class of stimulant. · For: ADHD; Autism Spectrum Disorder
Sites: Irvine, California; Los Angeles, California; Portland, Maine · 13 sites in all
- Treating Young Children With Attention Deficit Hyperactivity DisorderPivotal-lookingRecruiting
Children's Hospital Medical Center, CincinnatiAcademic, hospital or other
NCT07300956 · 370 participants (planned) · Start Feb 16, 2026 · Primary completion Feb 2030
Drug: Guanfacine (GUA); Methylphenidate (MPH) · For: Attention-Deficit/Hyperactivity Disorder (ADHD)
Sites: Palo Alto, California; Boston, Massachusetts; Kansas City, Missouri · 5 sites in all
- KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHDPivotal-lookingCompleted
Zevra TherapeuticsIndustry
NCT03460652 · 282 participants · Start Mar 13, 2018 · Primary completion Jun 20, 2019
Drug: KP415 oral capsule · For: ADHD
Sites: Little Rock, Arkansas; Colorado Springs, Colorado; Bradenton, Florida · 19 sites in all
- Efficacy, Tolerability and Safety of Dexmethylphenidate HCl Extended-Release Capsules in Children With Attention-Deficit/Hyperactivity DisorderPivotal-lookingCompleted
NovartisNovartis (NVS)
NCT00301236 · 252 participants · Start Feb 2006
Drug: Dexmethylphenidate HCl extended-release capsules · For: ADHD, ADD
Sites: Mesa, Arizona; Little Rock, Arkansas; Los Angeles, California · 25 sites in all
- An Efficacy and Safety Study w/ Azstarys® in Children 4-12 Years of Age With ADHDPivotal-lookingCompleted
Corium, Inc.Industry
NCT05685732 · 246 participants · Start Mar 22, 2023 · Primary completion May 2, 2024
Drug: Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH) · For: Attention Deficit/Hyperactivity Disorder
Sites: Little Rock, Arkansas; Anaheim, California; Centennial, Colorado · 20 sites in all
- Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity DisorderPivotal-lookingCompleted
University of California, Los AngelesAcademic, hospital or other
NCT00429273 · 212 participants · Start Jan 2007 · Primary completion Jul 2011
Drug: Guanfacine; Methylphenidate (MPH) · For: Attention Deficit Disorder With Hyperactivity
Sites: Los Angeles, California
- Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00776009 · 165 participants · Start Oct 2008 · Primary completion Dec 2008
Drug: Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR); Placebo · For: Attention-Deficit/Hyperactivity Disorder (ADHD)
Sites: Little Rock, Arkansas; Bradenton, Florida; South Miami, Florida · 8 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective91
- therapeutic response shortened61
- headache44
- anxiety43
- insomnia39
- irritability38
- decreased appetite34
- nausea34
- disturbance in attention28
- fatigue27
- product dose omission issue23
- suicidal ideation23
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2020 | 1 |
| 2021 | 5 |
| 2022 | 119 |
| 2023 | 239 |
| 2024 | 97 |
| 2025 | 154 |
| 2026 | 126 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Azstarys (Serdexmethylphen/Dexmethylphen)
2024 spending
$2.1M
Beneficiaries
1,058
4,949 claims
Per beneficiary
$1,992
$13.86 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $4,249 |
| 2022 | $159,660 |
| 2023 | $1,362,149 |
| 2024 | $2,107,123 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A Randomized, Controlled Laboratory Classroom Study of Serdexmethylphenidate and d-Methylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder.
Kollins SH, Braeckman R, Guenther S, et al. · J Child Adolesc Psychopharmacol 2021 · Randomized Controlled Trial
- Safety and Tolerability of Serdexmethylphenidate/Dexmethylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder: A 12-Month, Open-Label Safety Study.
Childress AC, Marraffino A, Cutler AJ, et al. · J Child Adolesc Psychopharmacol 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Pilot Trial of SDX/d-MPH Adult ADHD Examining Effects Throughout the Day.
Adler LA, Cho D, Leon T, et al. · Psychopharmacol Bull 2025 · Clinical Trial
- Dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder.
Silva RR, Muniz R, Pestreich L, et al. · J Am Acad Child Adolesc Psychiatry 2008 · Multicenter Study, Randomized Controlled Trial
- Analysis of Growth Velocity in Children with Attention-Deficit/Hyperactivity Disorder Treated for up to 12 Months with Serdexmethylphenidate/Dexmethylphenidate.
Childress AC, Cutler AJ, Patel M, et al. · J Child Adolesc Psychopharmacol 2023 · Clinical Trial, Phase III
- Absorption Differences between Immediate-Release Dexmethylphenidate and dl-Methylphenidate.
Patrick KS, Straughn AB · Drug Metab Dispos 2016 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
Sponsor: Commave Sub
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.